Navigation Links
Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results
Date:11/2/2007

HAYWARD, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) will announce its third quarter 2007 financial results on Thursday, November 8, 2007, after market close.

The announcement of Kosan's third quarter 2007 financial results will be followed by a conference call and live webcast on November 8, 2007 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Interested parties may access the live call by dialing 866.510.0707 (US) or 617.597.5376 (international), access code 93636825.

Interested parties may listen to the webcast live at http://www.kosan.com by clicking on the "Webcasts" tab under the heading, "Investors/Press."

The webcast is also being distributed over Thomson's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson's individual investor center at http://www.earnings.com or by visiting any of the investor sites in Thomson's Individual Investor Network. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents, at http://www.streetevents.com. A telephonic replay will be available through November 15, 2007 by dialing 888.286.8010, access code: 98027185. International callers can dial 617.801.6888, access code: 98027185.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that provides ... employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow job ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles ... surgery fellows for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, ... residency in Plastic and Reconstructive Surgery. The candidate will have the opportunity ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior ... Alzheimer’s Family Center. , Guests will be able to vote for their favorite ... Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek ...
(Date:8/21/2017)... ... ... The experts have spoken. Prolonged sitting and standing are a no-no for optimal ... way these days? FlexiSpot, one of the fastest-growing manufacturers of ergonomic office solutions, has ... Pro™– the world’s first sit-stand-cycle desk to backers worldwide. , The Launch , Part ...
(Date:8/21/2017)... San Diego, CA (PRWEB) , ... August 21, 2017 , ... ... Membership ( MAM ) health care reform plan, has announced his candidacy for the ... the American Dream and shared in America’s Promise. Coming to this country at age ...
Breaking Medicine News(10 mins):
(Date:8/11/2017)... CAESAREA, Israel , Aug. 11, 2017 ... company with mobile health and big data solutions, today ... results on Monday, August 14 and host a conference ... second quarter 2017 operating and financial results and its ... call will be hosted by Erez Raphael , ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
Breaking Medicine Technology: